Back to mobile site
Get it on Google Play

Soligenix reports positive safety review for phase 3 CTCL trial

October 7, 2025 7:30 AM EDT Send to a Friend
Soligenix Inc. (NASDAQ: SNGX) announced that its Data Monitoring Committee concluded there are no safety concerns with the ongoing confirmatory ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login